Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea

Cancer Biology and Therapy

Volumn 13, Issue 13, 2012, Pages 1269-1275

  Bowen, Joanne M ^a   Mayo, Bronwen J ^b   Plews, Erin ^b   Bateman, Emma ^b   Stringer, Andrea M ^c   Boyle, Frances M ^d   Finnie, John W ^e   Keefe, Dorothy M K ^b,e  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e HANSON INSTITUTE   (Australia)

Author keywords

Diarrhea; Intestine; Lapatinib; Rat model

Indexed keywords

LAPATINIB; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INDUCED DIARRHEA; DRUG INDUCED DISEASE; DRUG TOLERABILITY; HISTOPATHOLOGY; INTESTINE; INTESTINE CELL; MALE; NONHUMAN; OPTIMAL DRUG DOSE; ORGAN WEIGHT; RAT; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; DISEASE MODELS, ANIMAL; MALE; PACLITAXEL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RATS, WISTAR; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84868357349     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21783     Document Type: Article

References (33)

1. Metzger Filho O, Saini KS, Azim HAJ Jr., Awada A; on behalf of AROME. Prevention and management of major side effects of targeted agents in breast cancer. [Epub ahead of print]. Crit Rev Oncol Hematol 2011; PMID:20817545.
2. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13:3913-21; PMID:17606725; http://dx.doi.org/10.1158/1078-0432.CCR-06-2610.
3. Keefe DM, Gibson RJ. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer 2007; 15:483-90; PMID:17103195; http://dx.doi.org/10.1007/ s00520-006-0181-z.
4. Goss P, Smith I, O'Shaugnessy J, Ejlertsen B, Kaufmann M, Boyle F, et al. Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2-Overexpressing Breast Cancer. SABCS 2011 [abstract]
5. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 2006; 7:326-31; PMID:16640804; http://dx.doi.org/10.3816/CLC.2006.n.014.
6. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94; PMID:12467226.
7. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 2006; 18:2089-97; PMID:16815674; http://dx.doi.org/10.1016/j.cellsig. 2006.05.015.
8. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13:1114-9; PMID:18849320; http://dx.doi.org/10.1634/theoncologist.2008-0816.
9. Johnston S, Pippen J Jr., Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27:5538-46; PMID:19786658; http://dx.doi.org/10.1200/JCO.2009.23.3734.
10. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004; 9(Suppl 3):10-5; PMID:15163842; http://dx.doi.org/10.1634/theoncologist.9-suppl- 3-10.
11. Crown JP, Burris HA 3rd, Boyle F, Jones S, Koehler M, Newstat BO, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008; 112:317-25; PMID:18204897; http://dx.doi.org/10.1007/s10549-007-9860-9.
12. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, et al. First Results of the NeoALTTO Trial (BIG 01-06 / EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer. SABCS 2010 [abstract]
13. Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 2008; 5:268-78; PMID:18349858; http://dx.doi.org/10.1038/ncponc1087.
14. McCole DF, Barrett KE. Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function. Acta Physiol (Oxf) 2009; 195:149-59; PMID:18983445; http://dx.doi.org/10.1111/j. 1748-1716.2008.01929.x.
15. Hare KJ, Hartmann B, Kissow H, Holst JJ, Poulsen SS. The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. Clin Cancer Res 2007; 13:5170-5; PMID:17785573; http://dx.doi.org/10.1158/1078-0432.CCR-07-0574.
16. Roberts RB, Arteaga CL, Threadgill DW. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 2004; 5:115-20; PMID:14998487; http://dx.doi.org/10.1016/ S1535-6108(04)00032-7.
17. Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007; 6:1449-54; PMID:17881902; http://dx.doi.org/10.4161/cbt. 6.9.4622.
18. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003; 18:1095-100; PMID:12911669; http://dx.doi.org/10.1046/j.1440-1746.2003.03136.x.
19. Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23:5305-13; PMID:15955900; http://dx.doi.org/10.1200/JCO.2005. 16.584.
20. Burris HA 3rd, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 2009; 15:6702-8; PMID:19825948; http://dx.doi.org/10.1158/1078-0432.CCR-09-0369.
21. Koch KM, Reddy NJ, Cohen RB, Lewis NL, Whitehead B, Mackay K, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009; 27:1191-6; PMID:19188677; http://dx.doi.org/10.1200/JCO. 2008.18.3285.
22. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30:1426-47; PMID:18803986; http://dx.doi.org/10.1016/j.clinthera.2008.08.008.
23. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer2006; 14:890-900; PMID:16604351; http://dx.doi.org/10.1007/s00520-006- 0040-y.
24. Husain A, Aptaker L, Spriggs DR, Barakat RR. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel- containing chemotherapy regimens. Gynecol Oncol 1998; 71:104-7; PMID:9784328; http://dx.doi.org/10.1006/gyno.1998.5158.
25. Guchelaar HJ, ten Napel CH, de Vries EG, Mulder NH. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol (R Coll Radiol) 1994; 6:40-8; PMID:7909688; http://dx.doi.org/10.1016/S0936-6555(05)80367-X.
26. Zhang C, Xu YG, Duan XN, Liu YH, Zhao JX, Xu L, et al. Role of granulocyte colony-stimulating factor in paclitaxel-induced intestinal barrier breakdown and bacterial translocation in rats. Chin Med J (Engl) 2011; 124:1870-5; PMID:21866617.
27. Jamieson SM, Liu JJ, Connor B, Dragunow M, McKeage MJ. Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. Neurotoxicology 2007; 28:1092-8; PMID:17686523; http://dx.doi.org/ 10.1016/j.neuro.2007.04.009.
28. Tatsushima Y, Egashira N, Kawashiri T, Mihara Y, Yano T, Mishima K, et al. Involvement of substance P in peripheral neuropathy induced by paclitaxel but not oxaliplatin. J Pharmacol Exp Ther 2011; 337:226-35; PMID:21233199; http://dx.doi.org/10.1124/jpet.110.175976.
29. Chentanez V, Thanomsridejchai N, Duangmardphon N, Agthong S, Kaewsema A, Huanmanop T, et al. Ganglioside GM1 (porcine) ameliorates paclitaxelinduced neuropathy in rats. J Med Assoc Thai 2009; 92:50-7; PMID:19260244.
30. Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005; 116:464-70; PMID:15800945; http://dx.doi.org/10.1002/ijc.21082.
31. Gibson RJ, Stringer AM, Bowen JM, Logan RM, Yeoh AS, Burns J, et al. Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther 2007; 6:541-7; PMID:17457046; http://dx.doi.org/10.4161/cbt.6.4.3848.
32. Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33-41; PMID:17703303; http://dx.doi.org/10. 1007/s00280-007-0570-0.
33. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy- induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 2009; 63:239-51; PMID:18351341; http://dx.doi.org/10.1007/s00280-008-0732-8.